**Executive Summary**
This document outlines India's strategic shift towards becoming a global leader in precision medicine and biomanufacturing, driven by advancements in biotechnology and multi-omics research. The BioE3 policy aims to accelerate innovation and expand the bio-economy, with significant growth observed in the biotech startup sector. Key initiatives are strengthening biomanufacturing capabilities, with a ₹10,000 crore allocation for the Biopharma Shakti scheme. The Multi-Omics Summit 2026 served as a platform to discuss these developments.
**Key Points / Main Content**
**India's Healthcare Transformation**
* India is transitioning to a global hub for precision medicine, biomanufacturing, and medical innovation.
* The healthcare ecosystem integrates modern biotechnology, genomics, AI, and traditional knowledge systems like Ayurveda.
* India is moving from an era of seeking advanced treatment abroad to becoming a global healthcare destination.
**Bioeconomy and Policy Initiatives**
* The BioE3 policy (biotechnology for economy, environment, and employment) is launched to accelerate innovation and expand biomanufacturing capacity.
* The biotechnology ecosystem has seen dramatic expansion, with over 11,000 biotech startups.
* Government initiatives, including the Biopharma Shakti scheme with ₹10,000 crore funding, are strengthening biomanufacturing through hubs, biofoundries, and research infrastructure.
**Genomic and Multi-Omics Research**
* India's genetically diverse population provides a unique advantage in genomic research.
* Flagship initiatives like the Genome India Project and the upcoming Phenome India initiative aim to scale genomic sequencing significantly.
* Integrating genomics, transcriptomics, and proteomics with AI and Machine Learning will aid in understanding disease mechanisms and developing personalised treatments.
* Large-scale genomic data will help identify disease patterns, develop targeted therapies, and design early interventions.
**Biomedical Research and Collaboration**
* Breakthroughs in gene-based therapies and nuclear medicine are being observed.
* India is becoming a hub for collaborative global research in multi-omics, encouraging interdisciplinary partnerships.
* Reforms have opened the nuclear sector to private participation, fostering innovation in nuclear medicine research.
* India has demonstrated leadership in preventive healthcare with the development of the world's first DNA-based vaccine.
* The convergence of biotechnology, AI, genomics, and digital platforms is creating significant opportunities for healthcare innovation.
**Impact Analysis**
**Scientists and Researchers**
* **Impact:** Enhanced opportunities for advanced research in precision medicine, biomanufacturing, and multi-omics due to increased funding, infrastructure, and collaborative platforms. Access to large-scale genomic data will aid in identifying disease patterns and developing new therapies.
* **Action Required:** Participate in collaborative research initiatives, leverage new funding schemes like Biopharma Shakti, and contribute to national genomic projects.
**Biotechnology and Healthcare Industry**
* **Impact:** Expansion of biomanufacturing capacity, increased innovation in drug discovery and diagnostics, and potential for India to become a global healthcare destination. The development of integrated medicine models and advanced research infrastructure presents new business opportunities.
* **Action Required:** Invest in or develop biomanufacturing hubs and biofoundries, engage in public-private partnerships, and contribute to the growth of the bio-economy.
**Students and Academia**
* **Impact:** Increased opportunities for specialized education and training in emerging fields like multi-omics and precision medicine. The growth in the biotech sector is expected to create more employment prospects.
* **Action Required:** Pursue education and research in biotechnology, genomics, and related fields to align with national priorities and emerging job markets.
**Government and Policymakers**
* **Impact:** Validation of policies like BioE3 in driving growth and innovation. The success of initiatives demonstrates the potential for India to lead in biotechnology and healthcare on a global scale. Continued policy support is crucial for sustaining this momentum.
* **Action Required:** Continue to foster a conducive policy environment, ensure adequate funding for research and infrastructure, and encourage further public-private and international collaborations.
Key Entities Referenced
BioE3 Policy: A comprehensive policy focused on biotechnology for economy, environment, and employment.
Dr. Jitendra Singh: Union Minister of State (Independent Charge) for Science & Technology, Earth Sciences and MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space.
Biopharma Shakti scheme: A government initiative with an allocation of ₹10,000 crore to support biomanufacturing.
Genome India Project: A flagship initiative for genomic research in India.
Ministry of AYUSH: A dedicated ministry focused on traditional Indian medicine systems.
Ministry of Science & Technology
India Moving from Healthcare Follower to Global
Leader in Precision Medicine and
Biomanufacturing, says Union Minister Dr
Jitendra Singh
Over 11,000 Biotech Startups and BioE3 Policy Powering
India’s Bioeconomy Expansion: Dr Jitendra Singh
India’s Genetic Diversity Positions It to Lead Global
Collaboration in Multi-Omics Research: Dr Jitendra Singh
Posted On: 13 MAR 2026 6:21PM by PIB Delhi
India is entering a transformative phase where cutting-edge biotechnology, genomics and multi-omics
research are reshaping the future of healthcare, positioning the country as a global hub for precision
medicine, biomanufacturing and medical innovation, said Union Minister of State (Independent Charge)
for Science & Technology, Earth Sciences and MoS PMO, Personnel, Public Grievances, Pensions,
Atomic Energy and Space Dr. Jitendra Singh.
Delivering the inaugural address at the Multi-Omics Summit 2026, organised by the Proteomics Society,
India (PSI) with advocacy partnership of the IHW Council, Dr. Jitendra Singh said India has moved from
an era where advanced treatment required travelling abroad to a stage where the country is emerging as a
global healthcare destination attracting medical tourism through quality and cost-effective care.
He said India’s healthcare ecosystem today integrates modern biotechnology, genomics, and AI-driven
research with traditional knowledge systems such as Ayurveda, creating a unique model of integrated
medicine. The creation of a dedicated Ministry of AYUSH and the expansion of biotechnology research
platforms have enabled India to develop innovative healthcare solutions that combine tradition with
advanced science.
Highlighting the growing importance of biotechnology in national development, Dr. Jitendra Singh said
India is among the first countries to launch a comprehensive BioE3 policy, biotechnology for economy,
environment and employment. The policy is designed to accelerate innovation, expand biomanufacturing
capacity and generate new opportunities in the bio-economy.
The Minister said India’s biotechnology ecosystem has expanded dramatically in the last decade, with
more than 11,000 biotech startups today compared to only a few dozen earlier. Government initiatives are
strengthening biomanufacturing through dedicated funding, including the Biopharma Shakti scheme with
an allocation of ₹10,000 crore, which will support biomanufacturing hubs, biofoundries and advanced
research infrastructure.Referring to India’s large and genetically diverse population, Dr. Jitendra Singh said the country has a
unique advantage in genomic research. Through flagship initiatives such as the Genome India Project and
the upcoming Phenome India initiative, India has already completed sequencing of around 10,000
genomes and aims to scale this effort significantly. Such large-scale genomic data will help researchers
identify disease patterns, develop targeted therapies, and design early interventions even before clinical
symptoms appear.
He said integrating genomics, transcriptomics, and proteomics through multi-omics platforms, supported
by Artificial Intelligence and Machine Learning, will enable scientists to understand complex disease
mechanisms and develop personalised treatments suited to diverse populations.
Dr. Jitendra Singh also highlighted several emerging breakthroughs in biomedical research, including
advances in gene-based therapies and nuclear medicine. He cited recent progress in the treatment of
diseases such as sickle cell disorder and hemophilia, as well as new therapeutic developments in nuclear
medicine for acute lymphoblastic leukemia in children at the Tata Memorial Centre.
The Minister said India is increasingly becoming a hub for collaborative global research, particularly in
areas such as multi-omics that require interdisciplinary partnerships across institutions, sectors, and
countries. The government is encouraging such collaboration through policy reforms and expanded
participation from academia, industry, and startups.
He said recent reforms have also opened the nuclear sector to private participation, enabling greater
innovation in nuclear medicine research, which will play an important role in future healthcare
technologies when integrated with genomics and precision medicine.
Dr. Jitendra Singh said India has also demonstrated global leadership in preventive healthcare through the
development of the world’s first DNA-based vaccine, reflecting the country’s growing scientific
capabilities and its commitment to affordable healthcare solutions.
Calling the present period one of the most exciting phases in the evolution of modern medicine, Dr.
Jitendra Singh said the convergence of biotechnology, artificial intelligence, genomics, and digital
platforms is creating unprecedented opportunities for healthcare innovation.
He expressed confidence that India’s scientific talent, research ecosystem and forward-looking policies
will enable the country to not only collaborate globally but also lead future advances in biotechnology and
precision medicine.
The summit brought together leading scientists, researchers, clinicians, biotechnology innovators, and
industry experts to discuss the latest developments in multi-omics research and its potential to transform
healthcare, diagnostics, and drug discovery.PHOTO: Union Minister Dr Jitendra Singh delivering keynote address at the "Multi Omics Summit
2026", at New Delhi on Friday.*****
NKR/AK/AV
(Release ID: 2239776) Visitor Counter : 222
Read this release in: ही , Tamil